Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

Executive Summary

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.

You may also be interested in...



Novo Nordisk May Use Priority Review Voucher To Speed Oral Semaglutide To Market

Novo Nordisk’s chief science officer tells Scrip the readout of its PIONEER 6 trial on oral semaglutide came earlier than originally thought, allowing for an FDA filing in first-half 2019, and that use of a priority review voucher is a clear option that could speed up the process.  

With Novo Nordisk Dependent On GLP-1s, Even Perceived Price Pressures Can Hurt

Long-term top-line market forecasts for Novo Nordisk are heavily reliant on its GLP-1 portfolio's potential - so pricing uncertainties, especially in the US,  can unnerve sentiment, as seen when it reported Q2 results.

Novo Nordisk Touts First-Line Potential For Oral Semaglutide

Novo's oral GLP-1 receptor agonist has a lot going for it in diabetes based on the latest data, but still needs to prove cardiovascular benefit; a new large outcomes study is now in the works.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel